Benchmark Co. Maintains Anebulo Pharmaceuticals(ANEB.US) With Buy Rating, Maintains Target Price $8
Anebulo Pharmaceuticals Analyst Ratings
Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Anebulo Pharmaceuticals: Strong Buy Rating Amid Promising Clinical Advances and Rapid FDA Track
Rising Cannabis Hospitalizations and Leadership Transition Boost Anebulo Pharmaceuticals' Outlook: A Buy Rating Analysis
Anebulo Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Anebulo Pharmaceuticals, Maintains $6 Price Target
Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Initiates Coverage On Anebulo Pharmaceuticals With Buy Rating, Announces Price Target of $6
Anebulo Pharmaceuticals Analyst Ratings
Anebulo Pharmaceuticals (ANEB) Has a New Rating From H.C. Wainwright
Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target
Anebulo Pharmaceuticals Analyst Ratings
No Data
No Data